CN110607371A - Stomach cancer marker and application thereof - Google Patents

Abstract

The invention relates to a gastric cancer marker and application thereof, in particular to application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in preparation of a product for predicting response of a GC patient to neoadjuvant chemotherapy. The invention firstly determines the key molecular characteristics of C10orf71 gene mutation and the response of tumors to neoadjuvant chemotherapy, and based on the technical scheme of the invention, the neoadjuvant chemotherapy has the advantages of improving prognosis and determining responsive patients before the treatment starts, so that a better treatment scheme can be established. The protocol of the present invention optimizes the treatment strategy for individual GC patients as an important step.

Description

Stomach cancer marker and application thereof

Technical Field

The invention relates to the field of tumor molecular biology, in particular to a gastric cancer marker and application thereof.

Background

Gastric Cancer (GC) is one of the most common types of cancer in the world and is also the second most common cause of cancer-related death (8.2%). China is the most GC-afflicted country, and based on data from the central cancer registry of the chinese country, over 679,000 newly diagnosed GC cases occur, with about 498,000 GC-related deaths occurring each year. Most of these patients are in the advanced stage, with a 5-year survival rate < 30%. Although surgical treatment is the primary treatment for GC, multimodal strategies are employed to improve patient survival. Neoadjuvant (or perioperative) chemotherapy can "shrink the size of the tumor" before attempting radical resection. In addition, neoadjuvant chemotherapy helps reduce risk by eliminating potential cancer cells and providing a sensitive treatment regimen for postoperative adjuvant chemotherapy in GC patients with high risk of distant metastasis. The benefits of this approach compared to surgery alone have been demonstrated in a number of clinical trials. Currently, neoadjuvant chemotherapy is routinely used to eradicate patients with advanced GC.

Neoadjuvant chemotherapy is a widely used treatment option for GC patients, and several large clinical trials have shown that neoadjuvant chemotherapy has advantages in improving prognosis and identifying responsive patients before treatment begins, so better treatment regimens can be developed. However, a significant fraction of GC patients respond poorly to neoadjuvant chemotherapy. To date, only certain clinical features (e.g., age and preoperative weight loss) are available for patient selection, but function is very limited. Furthermore, it is unclear how neoadjuvant chemotherapy alters cancer signaling and affects the tumor microenvironment. A thorough understanding of these problems is crucial to developing an optimized multi-modal treatment plan. Therefore, there is an urgent need to characterize molecular markers that can predict therapeutic response and to interpret how GC evolves under the pressure of neoadjuvant chemotherapy.

Disclosure of Invention

In order to predict the response of GC patients to neoadjuvant chemotherapy and thus optimize the treatment strategy for individual GC patients, the present invention contemplates the following technical protocol.

The invention relates to application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in preparation of a product for predicting response of a GC patient to neoadjuvant chemotherapy.

The C10orf71 gene (muscle specific gene) is a gene known in the art, however, it has not been reported in the prior art to be related to the response of GC patients to neoadjuvant chemotherapy. Unexpectedly, the inventors of the present invention found that the C10orf71 mutation has a key role in influencing GC tumors in response to neoadjuvant chemotherapy.

In a preferred embodiment of the invention, the product further comprises a detection reagent for the copy number of MDM2 and/or MYC. By using the C10orf71 gene marker and MDM2 and MYC copy number detection reagents, it has higher prediction accuracy when used as a biomarker for predicting neoadjuvant chemotherapy response of gastric cancer patients.

In a preferred embodiment of the invention, the agent for neoadjuvant chemotherapy comprises cisplatin as a therapeutic agent. The inventors of the present invention found for the first time that the C10orf71 mutation is associated with resistance of the gastric cell line to cisplatin.

In a preferred embodiment of the invention, the drug for neoadjuvant chemotherapy comprises one, two or three of fluorouracil, capecitabine and oxaliplatin.

In another aspect of the invention, the invention also relates to the application of at least one of the primer kits for detecting C10orf71 gene, C10orf71 protein and C10orf71 gene in the preparation of a kit for detecting the resistance of a gastric cancer patient to cis-platinum.

In another aspect, the present invention relates to a kit for treating gastric cancer, which comprises at least one of C10orf71 gene, C10orf71 protein, C10orf71 gene detection primer reagents; also comprises one, two or three of fluorouracil, capecitabine and oxaliplatin.

In another preferred embodiment of the present invention, the primer for detecting C10orf71 gene is a primer for detecting mutation of C10orf71 gene.

Advantageous effects

The invention firstly determines the key molecular characteristics of C10orf71 gene mutation and the response of tumors to neoadjuvant chemotherapy, and based on the technical scheme of the invention, the neoadjuvant chemotherapy has the advantages of improving prognosis and determining responsive patients before the treatment starts, so that a better treatment scheme can be established. The protocol of the present invention optimizes the treatment strategy for individual GC patients as an important step.

Drawings

FIG. 1: sample collection and treatment effect assessment: (A) sample collection and omics data generation. The study included 35 GC patients who received neoadjuvant chemotherapy prior to surgery. Biopsy samples before treatment and surgically excised tumor samples after treatment were collected. Patients were divided into a response group (n-17) and a non-response group (n-18) based on strictly assessed radiological and pathological evidence. Multiple sets of data for pre-treatment and non-response-post-treatment samples were obtained by Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS) and RNA sequencing (RNAseq). (B) Representative radiological and pathological images from responsive and non-responsive patients. Arrows indicate the lesion sites. (C) Distribution of necrosis rates in the responsive and non-responsive groups. (D) Mandard tumor regression scores in the response and non-response groups.

Figure 2 mutation characteristics in GC samples before treatment: (A) specific gravity of six possible substitution types in different nucleotide backgrounds. Relative weights (B) and microsatellite instability (MSI) scores (C) of the codinc mutant features 17 between the non-responder group and responder group. The P values are based on the Wilcoxon rank-sum test. (D) Tumor mutation burden distribution between the two groups. P values are based on a single tail t test. (B) The centerline of the- (D) box is the median, the bottom and top of the box are the first and third quartiles, and whiskers extends to the 1.5 x quartile range of the lower and upper quartiles, respectively.

Figure 3 genes with significant mutations in GC samples before treatment: (A) passage through MuSiC2 (FDR) in tumor specimens prior to treatment<0.05) identified selected Significantly Mutated Genes (SMGs). The top and right bars show the observed mutation rate in each patient and the composition of the mutations in the selected genes, respectively. The genes are ordered by their mutation frequency, and different types of mutations are labeled with different grayscale colors. (B) C10orf71 showed significant mutation bias (p) in the non-responsive samples<0.045). The mutation sites are shown in genecaranton. (C) The C10orf71 mutation was associated with resistance of the gastric cell line to cisplatin, t-test, p 1.1x10^-4. (D) Cell cycle functional proteomics analysis based on 8 protein markers in a reverse phase protein array. (E) The C10orf71 mutation correlated with a lower cell cycle score in the gastric cell line, t-test, p ═ 0.015. (F) A proposed mechanistic model in which the C10orf71 mutation confers resistance to neoadjuvant chemotherapy by causing a less active cell cycle state.

Figure 4 significant somatic copy number changes in GC samples before treatment and their downstream signaling effects: (A) amplification signals for changes in somatic copy number plotted for the response versus the non-response groups. In the response group, the two oncogenes MYC and CCNE were located in unique peaks of 8q24.21 and 19q21, respectively, while the TP53 negative regulator MDM2 was in a unique peak of 12q15 in the non-response group. Myc (b) and MDM2(D) mRNA expression levels in the non-reactive and reactive groups. The P values are based on the single tailed Wilcoxon rank-sum test. The middle line in the box is the median, the bottom and top of the box are the first and third quartiles, and whiskers extends to the 1.5 x quartile range of the lower and upper quartiles, respectively. Enrichment of MYC target genes (C) and DNA repair pathways (E) in up-regulated genes in the reactive group relative to the non-reactive group. FDR was based on gene set enrichment analysis.

Figure 5 mutant evolution following neoadjuvant chemotherapy: (A) cancer gene mutation patterns before and after neoadjuvant chemotherapy. (B) After treatment, the top subnet is rich in mutational changes. The size of the circle represents the number of samples in the network where the mutation occurred. (C) Mutant allele frequency of the C10orf71 coding region before and after treatment in four patients. The P values are based on paired t-tests. The mutations of different patients are shown in different grey-scale colors. (D-E) schematic representation of the putative evolution of the C10orf71 mutation obtained in two patients.

FIG. 6 Gene expression and changes in tumor infiltrating immune cells following neoadjuvant chemotherapy: (A) volcano plots show genes differentially expressed between matched pre-and post-treatment samples. Important genes are shown in dark color (FC >2, FDR < 0.05). (B) A significantly down-regulated pathway following neoadjuvant chemotherapy. Genes that were significantly differentially expressed were identified at fold change >2 and FDR < 0.05. The bar color indicates the number of differentially expressed genes in the pathway. (C) Heat map showing fold change in mRNA expression of MYC target genes driven by treatment in MYC-amplified tumors (post-treatment/pre-treatment). Genes with significantly different expression (paired t-test, p <0.05) were marked with light (down-regulation) and dark (up-regulation). (D) Differential expression of GC therapeutic targets in pre-and post-treatment samples. P values were calculated based on paired Wilcoxon rank-sum. (E) Fraction of neutrophils and dendritic cells in the sample before and after treatment. P values were calculated based on paired t-tests. (D) And (E) the middle line of the box is the median, the bottom and top of the box are the first and third quartiles, and whiskers extends to the 1.5 x quartile range of the lower and upper quartiles, respectively.

Detailed Description

The present invention is described in more detail below to facilitate an understanding of the present invention.

Patient recruitment and sample cohort

GC patients of the study of this invention (> T2N + M0, UICC-AJCC version 8) were recruited in the university of beijing tumor hospital (beijing, china) in 2015 to 2018. The study was performed according to the declaration of helsinki and was approved by the ethical committee of the cancer hospital, beijing university (IRB approval No., 2019KT 05). All patients provided written informed consent prior to treatment, sample collection and analysis. Tumors were collected by biopsy and matched to adjacent non-tumor tissue prior to neoadjuvant therapy. For patients with no adjacent non-tumor tissue available, blood samples were taken for replacement. All patients then received a fluorouracil-based capecitabine/S-1 + oxaliplatin treatment regimen (XELOX [ oxaliplatin, 130mg/m2, intravenous, day 1; capecitabine, 1000mg/m2, oral, day 1 to 14 ] or SOX [ oxaliplatin 130mg/m2, day 1 intravenous drip; S-1, 40-60mg, 2 times daily, oral, day 1 to 14 ] for 2-4 cycles and evaluated the response to treatment before surgery. Cancer 73,2680-2686(1994). To reduce classification noise, only three pathologists were focused on consensus assessment patients, and finally 35 patients (17 responses and 18 non-responses) were included as a study cohort. Tumor samples were further collected post-operatively. For patients who responded, no post-treatment tumor samples were collected.

Multi-set mathematical data generation

For 35 GC patients, genomic DNA was extracted from tissue (or blood) samples using AllPrep DNA Mini Kit (QIAGEN) and QIAamp DNAblood Mini Kit (QIAGEN), respectively. For whole exome sequencing, 1. mu.g of DNA was cut into short fragments (150-250bp) using Bioruptor (Diagenode). Repairing the resulting DNA fragment. Adaptor fragments are then ligated to both ends of the fragment. DNA fragments of the target size are selected. Thereafter, Polymerase Chain Response (PCR) was performed, and the resulting mixture was purified. Exome capture was performed using SureSelect Human All exon v6(Agilent) according to the manufacturer's protocol. The hybridized mixture was then amplified by PCR. The validated DNA library was then sequenced on illumina novaseq 6000. For whole genome sequencing, 1. mu.g of genomic DNA was sheared to 150-250bp using Bioruptor (Diagenode). The DNA library was then generated using the standard protocol of Truseq nano dnakit (illumina). Paired-end sequencing (paired-end runs) was performed using Illumina NovaSeq 6000, and the library was sequenced to a minimum depth of 6 × base coverage. For RNA sequencing, total RNA was extracted from fresh tissue using the AllPrep RNA mini kit (QIAGEN). For each sample, a library was generated by TruSeq RNAv2 kit (illumina) using 3 μ g total RNA. The library was sequenced with Illumina NovaSeq 6000 and an average of 3,300 million 2 x 150bp paired ends per sample.

Analysis of variant data

The whole exome sequencing read pairs were trimmed and the remaining read pairs had < 3% N bases and > 50% high quality bases. The resulting high quality reads were aligned to the human reference genome (Homo _ sapiens _ assembly19) using Burrows-WheelerAligner 0.7.17 (h.li, r.durbin, Fast and acid short repair with Burrows-Wheeler transform. bioinformatics 25, 1754-. To improve The alignment accuracy, The BAM file was processed using a Genome Analysis Toolkit (version 3.8.1) (A.McKenna et al, The Genome Analysis Toolkit: a MapReduce frame for analyzing next-generation DNA sequencing data. Genome Res. 20,1297-1303(2010)) by: repeat entries are labeled, local re-alignments are performed around high confidence insertions and deletions and base quality is re-aligned. Based on about 7,000 high frequency SNP sites, matched pre-treatment, post-treatment and normal samples from the same patient were confirmed. A variant Calling piperine developed in the cancer Genomic map MC3 project was used to identify high confidence somatic base substitutions and insertions/deletions (K.Ellrott et al, Scalable Open science applying for Mutation Calling of Tumor elastomers Using Multiple Genomic piperines.CellSyst 6,271-281e277 (2018)). In short, this pipeline uses six callers to invoke the substitution mutation and three callers to identify the insertion/deletion with detailed annotation information. Only at least two caller-supported substitution mutations and insertions/deletions were retained for further analysis. WES somatic base substitutions were further validated based on RNA-seq data from the same samples. An alignment was generated using TopHat2 (D.Kim et al, TopHat2: acquisition alignment of transformations in the presentation of insertions, deletions and generations. genome Biol 14, R36 (2013)). For each substitution site, the coverage and number of mutation reads were calculated from the RNA-seqBAM file from the same sample. For sites with sufficient RNA-seq coverage (. gtoreq.10X), sites with at least two reads can be considered to have validated the base substitution of interest. The characteristics of the mutations in the pre-treatment samples were determined using R packagedeconstructSigs v1.8.0 as a matrix of mutation characteristics based on COSMIC characteristics (R.Rosenthal, N.McGranahan, J.Herreo, B.S.Taylor, C.Swanton, deconstructSigs: deletion biological processes in single molecules differentiation DNA repairdeficinces and patterns of cancer analysis. genome Biol 17,31 (2016)). The Microsatellite instability status of each tumor was assessed using MANTIS (E.A. Kautto et al, Performance evaluation for Rapid detection of pan-cancer specificity with MANTIS. on target 8,7452-7463 (2017)), and 2539 loci (S.J. Salipate, S.M. probes, H.L. Hampel, E.H. Turner, C.C. Pratcard, Microcuterite specificity detection sequencing. Clin chemistry m60,1192-1199 (2014)) obtained from the mSING GS package were used for this analysis. A clearly mutated gene (FDR <0.05) was identified in all pre-treatment samples using MuSiC2(18.N.D. Dees et al, MuSiC: identifying mutation in cancer genes. genome Res 22,1589-1598 (2012)). According to the Fisher's exact test, Maftools (A. Mayakonda, D.C.Lin, Y.Assenov, C.Plass, H.P.Koeffler, Maftools: effective and comprehensive analysis of physiological variations in cancer. genome Res28,1747-1756(2018)) were used to explore SMGs that showed clear mutational bias between non-responsive and responsive samples. To detect the gene group rich in the base substitution change after the treatment, HotNet2 (29) was used.

M.D. Leiserson et al, Pan-cancer networks analysis identities combinations of rare acidic pathologies and proteins Nat Genet47,106-114 (2015.) identify apparently mutated sub-networks based on the caloric value of each protein. Only genes with altered events were retained. An altered event is defined as a different non-silent variation of the same patient before and after treatment. The heat score is limited to major drivers or genes with at least two events of change. The consensus sub-network is visualized using the HINT + HI2012, MultiNet and iRefIndex interactive networks. Fisher's exact test was used to determine statistical significance.

Drug response determination and analysis

Cisplatin response data (AUC scores) were obtained for 21 gastric Cancer cell lines with CCLE mutation profile data from GDSC (W. Yang et al, Genomics of Drug Sensitivity in Cancer (GDSC): a resource for thermal biological discovery in Cancer cells. nucleic acids Res 41, D955-961 (2013)). In cell lines, 3 contained non-silent single nucleotide variations in C10orf71, while 18 were wild-type. The Student's t test was used to assess the difference between cell lines with the C10orf71 mutation and cell lines with the wild type.

Reverse phase protein array analysis

For the RPPA experiments, 18 gastric lines were first confirmed by short tandem repeats and then prepared. The antibody was verified as previously described (M.Ghandi et al, Next-generation Characterization of the Cancer Cell Lines encyclopedia. Nature 569, 503-. As previously described, RPPA data was generated by the RPPA core agency of the MD anderson cancer center. RPPA sections were first quantified using arraypro (meda cybernetics) to generate signal intensity, then processed by SuperCurve to estimate relative protein expression levels, and then normalized by median modification. The RPPA slide quality was evaluated by a quality control classifier, and only those slides above 0.8 (range: 0-1) were retained for further analysis. Protein markers were divided into 11 signal pathways and pathway scores were calculated based on the orientation of the protein members. The Student's t test was used to assess the difference between the cell line with the C10orf71 mutation and the wild type cell line, and FDR was used for multiple test corrections.

Somatic copy number Change analysis

Whole genome sequencing data was used to infer copy number values in samples before and after treatment. The whole exome sequencing read pairs were trimmed according to the criteria used for WES data. Reads were aligned to the human reference genome (Homo _ sapiens _ assombly 19) using BWA 0.7.17. SCNAs were then estimated by Control-FREEC (version 11.5) based on matching normal tumor pairs with a window size of 5kb (v. boeva et al, Control-FREEC: a tool for assessing copy number and adaptive content using next-generation sequencing data. bioinformatics 28,423-425 (2012)). Regions with statistically significant copy number variation frequencies were identified using gist 2.0 (c.h.memel et al, gist 2.0 defects sensitive and reliable localization of the targets of basic physical copy-number alteration in genomes Biol 12, R41(2011)) based on the corresponding segmentation values. The amplification and deletion thresholds were set at 0.1. Using the same tools, parallel analysis was performed on whole exome sequencing data as an independent dataset to verify the SCNA peaks identified by whole genome sequencing.

Clonal structure analysis of sample pre-and post-treatment

To explore the new adjuvant chemotherapy-driven clonal evolution, dynamic changes in clonal structure were inferred using sciClone (c.a. miller et al, sciClone: inducing cyclic architecture and tracking the activity and temporal patterns of tumor evolution. plos computer Biol 10, e1003665 (2014)). Copy number values based on whole exome sequencing data inferred by Control-FREEC were used to exclude SNVs from the copy number change region for clonal analysis. The inferred subclone evolution was further verified using another tool, PyClone (A.Roth et al, PyClone: statistical information of clinical position structure in cancer. Natmethods 11,396-398 (2014)).

Analysis of Gene expression

Gene expression was quantified based on RNA sequencing data using the alignment-free tool Kallisto (N.L.Bray, H.Pimentel, P.Melsted, L.Pachter, Near-optimal genomic RNA-seq quantification. NatBiotechnol 34,525-527 (2016)). The output of Kallisto was converted to gene-level counts and TPM (c.soneson, m.i.love, m.d.robinson, Differential analysis for RNA-seq: transcript-level assays. f1000res4,1521(2015)) using txmport. To identify genes that are differentially expressed between the responsive and non-responsive groups, a t-test was performed on each gene and they were ranked according to t-stability. The hallmark pathway of enrichment was determined using a pre-rank based Gene set enrichment assay (A. Subramanian et al, Gene set expression analysis: a knowledge-based assessment for expressing genome-wide expression profiles. Proc Natl Acad Sci U S102, 15545 15550 (2005)). To identify genes differentially expressed between tumor samples at different treatment stages in non-responders, a multifactorial model was fitted with patient ID as blocking factor, and then a Wald test was performed for treatment stage effects using DESeq2 (m.i. love, w.huber, s.anders, model evaluation of foam change and dispersion for RNA-seq data with DESeq2.genome Biol 15,550 (2014)). Genes with FDR <0.05 and fold change > 2.0 or < 0.5 were selected as differentially expressed genes. Overexpression analysis of the MSigDB marker Gene set achieved by cluster Profile (G.Yu, L.G.Wang, Y.Han, Q.Y.He, cluster Profile: an R package for formulating biological samples. OMICS 16,284-287(2012)) was performed separately for genes up-regulated and down-regulated in the post-treated samples (E.I.Boyle et al, GO:: TermFinder- -open source for accessing Gene on-restriction with a lift of genes. Bioinformatics 20,3710-3715 (2004)). The differential gene expression of MYC target genes before and after MYC-amplified non-responder treatment was further compared using Student's t-test. Tumor infiltrating immune cell abundance was inferred from mRNA expression data using TIMERs (b.li et al, comprehensive analyses of tumor immunity: immunology for cancer immunity. genobiology 17,174 (2016)). Paired Student's t-test was performed to identify differences in cellular composition between matching pre-and post-treatment samples.

Biopsy tumor samples from 35 pre-neoadjuvant-chemotherapy GC patients were subjected to multicohort sequencing (detailed patient and sample information is shown in fig. 1A). For these cases, whole exome sequencing was performed on tumor samples as well as matched germline DNA samples, which were used primarily to identify somatic base substitutions and small insertions/deletions. In 32 of 35 cases (3 excluded due to insufficient DNA quantity), whole genome sequencing was also performed, as well as matched germline samples for identification of somatic copy number changes (SCNA). In addition, RNA sequencing was performed on all tumor samples to characterize the mRNA expression profile of the protein-encoding genes. Following biopsy, patients received neoadjuvant chemotherapy based on 5-fluorouracil + oxaliplatin for 2-4 cycles. Cases were then divided into two categories based on a strict assessment of radiology and pathology evidence by three independent pathologists: response (n-17) and non-response (n-18). Representative radiological and pathological images are shown in fig. 1B. In the response group, the necrosis rate was higher than 65% in all cases, while in the non-response group, the necrosis rate was lower than 15% (fig. 1C). The Mandard tumor regression rating for the response group cases was <2, whereas the non-response group cases were 4 or 5 (FIG. 1D). Typically, patients in the response group are younger than those in the non-response group (Wilcoxon rank-sum test, 17:18 for non-response and non-response, 0.047 for p); patients in the non-responsive group tend to be advanced (Wilcoxon rank-sum test, non-responsive and non-responsive 17:18, p 0.023).

After receiving neoadjuvant chemotherapy in 18 patients in the non-responsive group, fresh tumor samples were obtained surgically from 14 of these and these post-treatment samples were subjected to whole exome sequencing (fig. 1A). For these cases, whole genome sequencing (for 13 cases) and RNA sequencing were also performed, respectively. In contrast, for the patients in the response group, tumor tissue was not obtained due to lesions with low tumor cell content resulting from good response to neoadjuvant chemotherapy. In summary, this experimental design enables the identification of a variety of molecular aberrations (bulk base substitutions SCNA and gene expression) involving tumor response to neoadjuvant chemotherapy from different perspectives (response versus non-response, pre-and post-treatment).

The composition of six possible base pair substitutions was examined and T was found>The G substitution showed the most pronounced pattern between the responsive and non-responsive groups, especially when the substitution sites flank C and T (fig. 2A). Consistently, COSMIC signature 1 when breaking down the mutation profile into different mutation signatures7(T>G) (11.L.B.Alexandrov et al, Clock-like biological processes in human gastric cells. Nat Genet47, 1402-1407 (2015)) is a feature previously observed in esophagus and stomach cancer and associated with byproducts of oxidative damage (12.M.Tomkova, J.Tomek, S.Kriaucinations, B.Schuster-Bockler, Mutamaterial signature distribution design DNA replication timing and strand methodology. genome Biol 19,129 (2018)). The response group contributed much higher than the non-response group (Wilcoxon rank-sum test, p 0.049, response vs non-response 17:18, fig. 2B). Next, the distribution of microsatellite instability (MSI) scores in these tumors as calculated by MANTIS was examined (13.E.A. Kautto et al, Performance evaluation for rapid detection of pan-candidate microsaltite with MANTIS. Oncostatt 8,7452-7463 (2017)). Surprisingly, MSI scores were found to be significantly higher in the non-responsive group than in the responsive group (Wilcoxon rank-sum test, p 0.022, non-responsive vs. 17:18, fig. 2C). Thus, the non-responsive group was tested for the presence of higher mutation burden and confirmed this pattern (Student's t test, non-response vs non-response 17:18, p 0.04, fig. 2D and fig. 3A). Preclinical data indicate that MSI-H status of large intestine tumors are resistant to 5-fluorouracil-based chemotherapy (m.hewish, c.j.Lord, S.a.Martin, D.cunningham, A.ashworth, Mismatch reparticent clinical cancer in the same of personalised treated tumor. nat Rev clinical cancer 7,197208 (2010); M.Koopman et al, Predictive and qualitative markers for the outome of therapy in advanced clinical Cancer, a retrospecific analysis of the phase III random CAIRO studyr, Eur J Cancer 45,1999-2006(2009). Clinically, only MSI-negative colorectal cancer patients benefit, while MSI-H does not benefit (16.C.M. Ribic et al, Tumor microsatellite-instability status a predictor of recent from fluorogenic-based adjuvant chemotherapy for colon cancer. N Engl J Med 349, 247-349 (2003)), which makes MSI-H status a powerful predictor of non-response to 5-fluorouracil-based chemotherapy (G.Des G349)uetz et al, Does microsystem induced pathology in clinical Cancer? A systematic review with meta-analysis Eur J Cancer 45, 1890-.

To identify individual mutant genes that may play a role in influencing therapeutic response, the apparently mutated genes (SMG) (p 2.9 10) were next identified using MuSiC2(18.n.d. des et al, MuSiC: identifying biological mutation in cancer. genome Res 22,1589-1598 (2012))^-4FDR ═ 0.05). The most mutated genes included TP53, PI3KCA, RNF43, ARIDA1 and KRAS as previously reported in other gastric cancer cohorts (19.N. cancer Genome Atlas Research, Comprehensive molecular characterization of organic Adenocercinoma. Nature513,202-209(2014)) (FIG. 3A). Among the SMGs identified in this and previous studies (19.n. cancer Genome Atlas Research, Comprehensive molecular characterization of biological adonnarcinoma. nature513,202-209(2014)), C10orf71 is the only gene showing a clear pattern between the responsive and non-responsive groups: mutations occurred in all 5 non-responsive samples, but not in the responsive samples (Fisher exact test, p 0.04, FDR)<0.25), and no recurrent mutations were detected (fig. 3B). To validate this observation, based on drug response data using a panel of 21 gastric cancer cells (20), it was indeed observed that cell lines with the C10orf71 mutation were more resistant to cisplatin (the equivalent platinum drug included in the neoadjuvant chemotherapy regimen) than these wild-type cell lines (Student's t test, n_mut vs.n_WT＝3：18，p＝1.1*10^-4Fig. 3C). To gain more mechanistic insight, functional proteomic data of gastric cell lines were analyzed using reverse phase protein arrays. Cell lines with the C10orf71 mutation were found to show significantly lower cell cycle scores (based on 8 protein markers) than those of the wild type (Student's t test, n)_mut vs.n_WT3: 18, p ═ 0.015, fig. 3D, E). Since cell cycle arrest is the main mechanism of action of platinum drugs,without wishing to be bound by theory, the inventors speculate that the C10orf71 mutation therein confers resistance to neoadjuvant chemotherapy by causing a less active cell cycle state (fig. 3F). These results indicate that mutations in this gene are potential biomarkers of resistance to neoadjuvant chemotherapy.

Key SCNA associated with neoadjuvant chemotherapy response

Using low-pass whole genome sequencing data (tumors, range: 5-9, median, 7; normal, range: 5-9, median 7), SCNA that could distinguish between the responsive and non-responsive groups was next studied. Distinct amplified or missing peaks were determined for these two groups using gist 2.0(c.h. memel et al, gist 2.0 defects sensitive and reliable localization of the targeting of fluidic copy-number alteration in human subjects Biol 12, R41(2011)) (FDR ═ 0.1). Although the missing peak profiles of responsive and non-responsive tumors were similar, the response group contained two distinct amplification peaks: one at 8q24.21, comprising a major driver gene MYC; the other is 19q12 with cancer gene CCNE 1. Meanwhile, the non-responsive group contained a unique amplification peak at 12q15, comprising the negative regulator MDM2 of TP53 (P. Chene, inhibition of the p53-MDM2interaction: an antigen target for Cancer therapy. Nat Rev Cancer 3,102-109 (2003)) (FIG. 4A). Similar peaks were observed using parallel whole exome sequencing data. This analysis implies further analysis of the original SCNA candidates.

If these amplification peaks play a role in influencing the response to neoadjuvant chemotherapy, corresponding signals will be observed in their associated downstream pathways. Thus, using RNA sequencing data, mRNA expression profiles of these pre-treatment samples were next examined. Although no significant differences in MYC expression were observed between the two groups (fig. 4B, t-test, p ═ 0.6), MYC target genes showed a significant abundance of up-regulated genes in the responsive group relative to the non-responsive group (fig. 4B, t-test, p ═ 0.6). In FIG. 4C, gene set enrichment analysis, nominal p 0.0, FDR < 10^-3) Indicating that MYC signaling was indeed activated in the response group. In a variety of conditions including breast cancer, small cell lung cancer and colorectal cancerIn disease, a relationship between MYC amplification and better response to similar chemotherapy has been reported. Consistent with the amplification peak of the non-responsive group, MDM2 showed significantly higher mRNA expression levels in this group (fig. 4D, Student's t test, response vs non-responsive 17:18, p 0.033). Furthermore, the DNA repair pathway showed a corresponding up-regulation in the response group relative to the non-response, supporting a negative regulatory effect of MDM2 on DNA repair (fig. 4E, gene set enrichment analysis, nominal p 0.0, FDR<10^-3). In breast and pancreatic cancer, MDM2 amplification has been reported to correlate with poor clinical outcome and chemotherapy. No significant changes in the CCNE1 gene itself or its associated pathway were observed. Taken together, these results suggest that some key SCNAs may contribute to sensitivity (e.g., MYC amplification) or resistance (e.g., MDM2 amplification) to GC neoadjuvant chemotherapy.

Major somatic base substitution changes following neoadjuvant chemotherapy

Genomic evolution of GC under neoadjuvant chemotherapy was examined using parallel whole exome sequencing data of 14 matched pre-and post-treatment sample pairs (mean coverage > 200). Overall, no significant change in mutation burden or mutation characteristics was found. For the known cancer drivers, some tumors showed critical mutational changes (loss or gain of mutation) before and after treatment, while other tumors showed the same mutational signature (fig. 5A). To systematically identify genes or pathways that exhibit the most frequently occurring mutational changes, HotNet2 was used to search for protein interaction networks that are rich in such signals (29.M.D. Leiserson et al, Pan-cancer network analysis identities association pathways and protein complexes Nat Gene 47,106-114 (2015)). One top subnet identified consisted of IRS1, IRS2, PIK3CA, JAK1 and IL6ST (fig. 5B). In particular, IRS1 plays a key role in signaling insulin and insulin-like growth factor-1 (IGF-1) receptors to the PI3K/AKT pathway, which continually acquired new mutations in five post-treatment samples (Fisher's exact test, p 0.041), suggesting the existence of a recurrent resistance mechanism. Analysis of responsive and non-responsive pretreatment samples indicated that mutations in C10orf71 contribute to improved treatment resistance. If so, it would be desirable to increase the frequency of allelic mutations or obtain new mutations in the post-treatment sample, since tumor cells that are susceptible to chemotherapy (i.e., those tumor cells that do not have such mutations) would likely be removed by selection during the course of treatment. Of the 14 pairs of samples investigated, 4 showed a C10orf71 mutation in the pre-or post-treatment samples, two of which acquired a new mutation after neoadjuvant chemotherapy. A significant increase in mutant allele frequency was indeed observed at the eight mutation sites detected compared to the pre-treatment samples (figure 5C, Student's st test, n-8 pairs, p < 0.05; the same pattern was true even after tumor purity was adjusted). Fig. 5D and 5E show schematic diagrams of the putative evolution of the two cases, in which the obtained C10orf71 mutation gradually increased its allele frequency. Although the true evolutionary trajectory is difficult to validate, this result suggests that the C10orf71 mutation has a key role in influencing tumor response.

Key gene expression and cellular composition changes following neoadjuvant chemotherapy

Finally, using parallel RNA sequencing data (3,300 million reads per sample) for 14 pre-and post-treatment sample pairs, the gene expression profile of the perturbation after neoadjuvant therapy was studied. 869 differentially expressed genes were identified (DESEQ2, n-14 pairs, fold change>2，p<5*10^-3，FDR<0.05, fig. 6A). These genes were significantly enriched in several downregulated pathways, including inflammatory response, allograft rejection, KRAS signaling, and IL6/JAK/STAT3 signaling (fig. 6B). Analysis of responsive and non-responsive pre-treatment samples indicated that MYC expansion and subsequent MYC signaling activation sensitized tumor cells to treatment. If so, it is expected that in tumor samples with MYC amplification, MYC signals will be "inactivated" by selection during the purification evolution. Indeed, it was found that for 7 MYC-amplified tumors, nearly half of the MYC target genes (47.2%, 93/197) were significantly down-regulated in tumors after non-responsive treatment (Student's t test, n-7 pairs, p)<0.05) and this ratio is much higher compared to other genes (Fisher's exact test, p)<10^-3). On the contrary, the present invention is not limited to the above-described embodiments,in these samples, only 3% of MYC target genes were significantly upregulated (fig. 6C). These results further support a link between MYC expansion and sensitivity to neoadjuvant chemotherapy. Expression of several therapeutic targets currently used for GC treatment was also examined and found to be significantly down-regulated for HER2, VEGFR1 and VEGFR2 (paired Wilcoxon rank-sum test, n ═ 14 pairs, p ═ 14 pairs<0.05，FDR<0.1; fig. 6D and 5A).

To investigate the effect of neoadjuvant chemotherapy on the tumor microenvironment, tumor infiltrating immune cell abundance (including B cells, CD 8T cells, CD 4T cells, neutrophils, macrophages, and dendritic cells) was inferred from mRNA expression data using TIMERs. Surprisingly, significant reductions in the cellular composition of neutrophils and dendritic cells were found (fig. 6E, Student's T test, n-14 pairs, p <0.05, FDR <0.12), with a slight reduction in CD 8T cells (n-14, p <0.1, FDR <0.2) post-treatment. In summary, RNA sequencing analysis indicates that neoadjuvant chemotherapy can not only remodel immune signals in GC cells, but also alter their immune microenvironment.

The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.

Claims (7)

1. Use of at least one of a C10orf71 gene, C10orf71 protein, C10orf71 gene detection primer kit in the manufacture of a product for predicting the response of a GC patient to neoadjuvant chemotherapy.

2. The use according to claim 1, wherein the product further comprises a detection reagent for the copy number of MDM2 and/or MYC.

3. The use according to claim 1 or 2, wherein the medicament for neoadjuvant chemotherapy comprises cisplatin as a therapeutic agent.

4. The use according to claim 1 or 2, wherein the medicament for neoadjuvant chemotherapy comprises one, two or three of fluorouracil, capecitabine and oxaliplatin.

Application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in preparation of a kit for detecting the resistance of a gastric cancer patient to cis-platinum.

6. A kit for diagnosing and/or treating gastric cancer, comprising at least one of C10orf71 gene, C10orf71 protein, C10orf71 gene detection primers; also comprises one, two or three of fluorouracil, capecitabine and oxaliplatin.

7. The kit according to claim 6, wherein the C10orf71 gene detection primer is a primer for detecting mutation of C10orf71 gene.